

Serial No.: 09/581,976

Group Art Unit: 1648

In the Claims:

Claims 2, 12 and 16-20 have been canceled.

Claims 1, 6, 8, 10, 11 and 13-15 have been amended as follows:

1. (Twice Amended) A composition comprising an isolated fusion protein, wherein said composition comprises a Human Papilloma Virus (HPV) protein selected from the group consisting of: E6 protein, E7 protein, and E6/E7 fusion protein, linked to a protein D or a fragment thereof having T helper epitopes from *Haemophilus influenza* B, lipoprotein D or fragment thereof having T helper epitopes from *Haemophilus influenza* B, and an immunostimulatory cytosine-guanosine (CpG) containing oligonucleotide.

6. (Amended) A composition as claimed in claim 1 additionally comprising a histidine tag of at least 4 histidine residues.

8. (Thrice Amended) A composition as claimed in claim 1 wherein the immunostimulatory CpG oligonucleotide comprises a hexamer motif: purine purine cytosine guanine pyrimidine pyrimidine.

9. (Amended) A composition as claimed in claim 1 wherein the CpG oligonucleotide contains a phosphorothioate inter-nucleotide linkage.

10. (Amended) A composition as claimed in claim 1 wherein the CpG oligonucleotide is selected from the group consisting of:

OLIGO 1: TCC ATG ACG TTC CTG ACG TT;

OLIGO 2: TCT CCC AGC GTG CGC CAT; and

OLIGO 3: ACC GAT GAC GTC GCC GGT GAC GGC ACC ACG

11. (Amended) A method of inducing an immune response in a patient to an HPV antigen comprising administering a safe and effective amount of a composition as claimed in claim 1.